Back to the main directory
Company Analysis / Equity
- ROBERTET. Pursuit of Naturals! (+) by MidCap Partners
- I.CERAM. First visible effects of unloaded sternum sales (+) by MidCap Partners
- Pakistan Equity Market: Weekly Review - Foreign Buying Propels the Index by 2.4% by Elixir Securities
- Lage, Lage, Lage: Ximen Mining hat den Schlüssel zum Erfolg by Rockstone Research
- Location is Key for Ximen‘s Treasure Mountain Project in Southern British Columbia by Rockstone Research
- Slovenian Weekly Regional Overview 28.1.2019 - 1.2.2019 by Alta Invest
- Baidu FVE Reduced 19% to $262, but Shares Still Look Undervalued by Morningstar
- Morningstar | Baidu FVE Reduced 19% to $262, but Shares Still Look Undervalued by Morningstar
- Slightly Below-Par 3Q for KDDI; Potential Price Cuts, Rakuten Entry Overhang; FVE Still JPY 3,400 by Morningstar
- Morningstar | Decent 4Q for Altria; Short-Term Guidance Looks Conservative but Juul Deal Still Appears Expensive by Morningstar
- Brookfield Likely to Acquire Healthscope by Morningstar
- Morningstar | Slightly Below-Par 3Q for KDDI; Potential Price Cuts, Rakuten Entry Overhang; FVE Still JPY 3,400 by Morningstar
- Morningstar | Healthscope Fair Value Increased to AUD 2.50 on Likelihood of Brookfield Acquisition Succeeding. See Updated Analyst Note from 01 Feb 2019 by Morningstar
- Morningstar | Big Miss for Stora in 4Q, but Mostly Temporary Factors by Morningstar
- CMBC’s Weaker-Than-Expected 4Q Earning Alerts Indicated Rising Credit Quality Risks; Reduced FVE by Morningstar
- Morningstar | CMBC’s Weaker-Than-Expected 4Q Earning Alerts Indicated Rising Credit Quality Risks; Reduced FVE. See Updated Analyst Note from 01 Feb 2019 by Morningstar
- Jiangxi Copper's Preliminary 2018 Results Below Expectations; Shares Overvalued by Morningstar
- Morningstar | CMBC’s Weaker-Than-Expected 4Q Earning Alerts Indicated Rising Credit Quality Risks; Reduced FVE. See Updated Analyst Note from 01 Feb 2019 by Morningstar
- Agenda - 01/02/2019 by Aurel BGC
- Morningstar | Jiangxi Copper's Preliminary 2018 Results Below Expectations; Shares Overvalued by Morningstar
- Morningstar | McKesson Reports Solid Quarterly Results With Steady Top-Line Core Drug Distribution Growth by Morningstar
- Morningstar | Sherwin-Williams' Sales Growth Will Pick Up in 2019 Following Fall Slowdown; Maintaining FVE. See Updated Analyst Note from 01 Feb 2019 by Morningstar
- Standard Stewardship Rating and FVE for Komatsu Remain Intact Following Change in Management by Morningstar
- Led by Keytruda and Gardasil, Merck Posts Strong Fourth Quarter, Supporting FVE Increase by Morningstar
- Morningstar | Led by Keytruda and Gardasil, Merck Posts Strong Fourth Quarter, Supporting FVE Increase by Morningstar